Browsing Tag
medtech
10 posts
How the Japan patent allowance could strengthen RenovoRx’s oncology platform valuation story
Could RenovoRx’s Japan patent strengthen the RNXT valuation story? Read what this means for growth, competition, and investor sentiment.
LivsMed completes $94m KOSDAQ IPO, eyes US entry and robotic expansion
LivsMed raised $94M in Korea’s largest 2025 IPO to fund global expansion. Find out how it plans to challenge surgical incumbents with its platform strategy.
Inspira Technologies and Bites launch AI-driven training revolution across MedTech networks
Find out how Inspira Technologies’ AI-driven partnership with Bites is transforming global MedTech training and redefining device adoption standards.
Boston Scientific to take full control of Nalu Medical in $533m chronic pain tech deal
Boston Scientific is acquiring Nalu Medical for $533M to expand its pain therapy portfolio with a miniaturized, wearable neurostimulation system. Learn what this means.
ZimVie investors back $19 a share ARCHIMED deal, setting stage for major medtech shake-up
Find out how ZimVie’s shareholders approved a $19-per-share ARCHIMED acquisition and what it means for medtech investors and M&A sentiment.
From Verizon to Butterfly Network: Can John Doherty’s Wall Street discipline steady a medtech pioneer?
Butterfly Network (NYSE:BFLY) names Wall Street veteran John Doherty as CFO to steer the medtech innovator toward profitability and financial discipline.
Axon Therapies bags $32m to push heart failure trials—can this MedTech deliver where drugs failed?
Axon Therapies raises $32M to advance implant-free heart failure therapy. Learn how its splanchnic ablation trials could reshape cardiology.
dorsaVi (ASX: DVL) stock surges after Select Medical deal opens U.S. distribution for wearable rehab technology
dorsaVi (ASX: DVL) signs major five-year agreement with Select Medical for motion-sensor rehab tech. Find out why its stock is up 354% in a year.
Heartflow’s upsized IPO raises $316.7m, valuing AI-driven medtech firm at $1.54bn
Learn how Heartflow’s upsized IPO raised $316.7 million and achieved a $1.54 billion valuation—and what it means for AI-driven medtech investors.
How Cardiex, ResMed, ImpediMed, and Volpara are shaping Australia’s MedTech future in 2025
Comparing Cardiex, ResMed, ImpediMed, and Volpara in 2025 to see which ASX medtech firm is best positioned for growth in diagnostics, AI, and digital health.